長時間作用型医薬品市場：技術とサービス、2023-2035年：適合剤形別分布（長時間作用型注射剤、長時間作用型埋め込み型注射剤、長時間作用型経口剤、長時間作用型局所剤/経皮剤、その他の剤形）、原理（送達システムからの薬物放出の操作、生体内クリアランスの操作）、戦略（化学修飾、マイクロカプセル化、長時間作用型ハイドロゲル、長時間作用型インプラント、長時間作用型マイクロニードル、多胞リポソーム、ナノ結晶懸濁液、タンパク質融合）、送達される分子の種類（低分子、生物製剤、その他の分子）、使用される材料の種類（ポリマーベース、非ポリマーベース）、主要地域（北米、欧州、アジア太平洋、中東・北アフリカ）：産業動向と世界予測、2023-2035年

Long Acting Drugs Market: Technologies and Services, 2023-2035: Distribution by Compatible Dosage Form (Long Acting Injectables, Long Acting Implantable, Long Acting Orals, Long Acting Topicals / Transdermals and Other Dosage Forms), Principle (Manipulation of drug release from delivery systems and Manipulation of in vivo clearance), Strategy (Chemical Modification, Micro-encapsulation, Long Acting Hydrogels, Long Acting Implants, Long Acting Microneedles, Multivesicular Liposomes, Nanocrystal Suspensions and Protein Fusion), Type of Molecule Delivered (Small Molecules, Biologics and Other Molecules), Type of Material Used (Polymer based and Non-polymer based), and Key Geographical Regions (North America, Europe, Asia-Pacific and Middle East and North Africa): Industry Trends and Global Forecasts, 2023-2035

長時間作用型医薬品市場は、予測期間2023-2035年にCAGR 13％で成長するとみられる。近年、医薬品業界では、従来の薬物送達方法から長時間作用型薬物送達システムの採用へと、顕著なシフトが進んでいる。これ... もっと見る

出版社	出版年月	電子版価格	ページ数	言語
Roots Analysis ルーツアナリシス	2023年1月1日	US$4,799 シングルユーザライセンスライセンス・価格情報・注文方法はこちら	291	英語

サマリー

長時間作用型医薬品市場は、予測期間2023-2035年にCAGR 13％で成長するとみられる。

近年、医薬品業界では、従来の薬物送達方法から長時間作用型薬物送達システムの採用へと、顕著なシフトが進んでいる。これらのシステムは、1回の投与で長期間にわたって薬効を持続させ、患者の体内で数週間、数カ月、あるいは数年にわたって最適な治療レベルを維持することができる。この転換期は、眼科、腫瘍学、神経学、感染症などさまざまな医療領域に大きな影響を与え、治療の有望な道を提示している。

長時間作用型薬物送達システムの採用は、数多くの利点をもたらす。これには、患者の服薬アドヒアランスとコンプライアンスの向上、投与回数の減少、不規則な薬剤使用に伴うリスクの最小化、患者の利便性の向上などが含まれる。さらに、女性のための多目的予防技術としての長時間作用型膣リングの台頭は、医療分野におけるこのような技術革新の範囲と需要の拡大を浮き彫りにしている。これらの長時間作用型製剤の成功に不可欠なのは、マイクロカプセル化、ナノ結晶懸濁液、長時間作用型ハイドロゲル、マイクロニードルなどの方法論の戦略的導入と相まって、長時間作用型インプラント、注射剤、膣剤、経口剤、局所/経皮剤など、適切な剤形を細心の注意を払って選択することである。このような思慮深い組み合わせにより、薬物の生体内分布が促進され、標的を絞った治療効果が得られやすくなる。

このような最先端技術の開発における絶え間ない技術革新のペースに後押しされ、長時間作用型薬物ソリューションに対する市場の急増する需要に後押しされて、長時間作用型薬物技術・サービス市場は予測期間中に大幅に拡大する態勢を整えている。

レポート範囲
 調査で得られた主要な洞察のエグゼクティブサマリー。長時間作用型薬物送達技術およびサービス市場の現状と、中長期的に予想されるその進化についてハイレベルな見解を提供しています。
 長時間作用型薬物送達の概要と長時間作用型薬物送達システムの種類。さらに、長時間作用型薬物送達に関連する基本原理と戦略にも焦点を当てている。
 本書では、原理、戦略、使用材料の種類、適合する剤形、投与間隔の延長、送達される分子の種類、開発の最高段階、承認された薬剤の数、治療領域など、いくつかの関連パラメータに基づき、長時間作用型薬物送達技術の現在の技術状況を詳細に評価する。
 設立年、企業規模、本社所在地、施設所在地、サービスプロバイダーの種類、事業規模、適合剤形、提供サービス、対応分子の種類など、いくつかの関連パラメータに基づき、長時間作用型薬物送達に関連する受託サービスを提供する企業のサービスプロバイダー全体の状況を詳細に評価。
 開発者パワーと技術力に基づく長時間作用型薬物送達技術の詳細な技術競争力分析。
 長時間作用型薬物送達サービスプロバイダーの詳細な企業競争力を、企業力とサービス力に基づき分析。
 長時間作用型薬物送達の領域で技術を開発し、サービスを提供している北米、欧州、アジア太平洋地域の著名な（独自の基準に基づいてショートリスト化された）プレイヤーの詳細プロフィール。各プロフィールは、企業の簡単な概要、技術ポートフォリオ、サービスポートフォリオ、最近の開発、情報に基づく将来の見通しに関する詳細を特徴としています。
 2018年以降、この領域に従事する利害関係者間で締結された最近のパートナーシップの詳細な分析。買収、製造契約、製品開発・商業化契約、サービス提携、技術ライセンス契約、その他の関連契約を網羅。
 長時間作用型薬物送達に関連する研究に関する570以上の査読付き科学論文を、出版年、出版タイプ、人気のキーワードなど、いくつかの関連パラメータに基づいて詳細に分析。また、トップジャーナル、トップ出版社、トップ著作権者、主要資金提供機関（論文数ベース）に関する情報も提供しています。
 2018年以降、長時間作用型薬物送達に関連して出願／付与された様々な特許について、公開年、地域、CPC記号、組織の種類、主要なプレーヤーなどのパラメータを考慮した洞察に満ちた分析。
 補助金授与年、授与額、支援期間、資金提供機関センターのタイプ、補助金申請、補助金授与の目的、補助金活動コード、NIH支出カテゴリー、関与する研究セクション、人気のあるNIH部門、受領組織のタイプなどの複数のパラメータに基づいて、2018年以降、長時間作用型ドラッグデリバリーに焦点を当てたプロジェクトのために様々な研究機関に授与された学術補助金の詳細なレビュー。
 包括的な市場予測と機会分析で、2035年までの市場の将来性を強調。原理、戦略、適合する投与形態、送達される分子のタイプ、使用される材料のタイプ、主要地域に基づいて、現在および今後の機会を分別しています。

主要市場企業
 Adare Pharma Solutions
 AMW
 Bostal Drug Delivery
 Creative Biolabs
 ForDoz Pharma
 イノコア・ファーマシューティカルズ
 インテグラル・バイオシステムズ
 ラティチュード・ファーマシューティカルズ
 ナビン・サクセナ研究技術センター（NSRT）
 サムヤン・バイオファーム

ページTOPに戻る

1. PREFACE
1.1. Introduction
1.2. Key Market Insights
1.3. Scope of the Report
1.4. Research Methodology
1.5. Frequently Asked Questions
1.6. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. Overview of Long Acting Drug Delivery
3.2.1. Types of Long Acting Drug Delivery Systems
3.3. Long Acting Drug Delivery Technologies
3.3.1. Underlying Principle
3.3.2. Associated Strategies
3.4. Concluding Remarks
4. TECHNOLOGY LANDSCAPE
4.1. Chapter Overview
4.2. Long Acting Drug Delivery: Technology Landscape
4.2.1. Analysis by Principle
4.2.2. Analysis by Strategy
4.2.3. Analysis by Type of Material Used
4.2.4. Analysis by Compatible Dosage Form(s)
4.2.5. Analysis by Extended Dosing Interval(s)
4.2.6. Analysis by Type of Molecule(s) Delivered
4.2.7. Analysis by Highest Phase of Development
4.2.8. Analysis by Number of Approved Drugs
4.2.9. Analysis by Therapeutic Area(s)
4.3. Long Acting Drug Delivery: Technology Developers Landscape
4.3.1. Analysis by Year of Establishment
4.3.2. Analysis by Company Size
4.3.3. Analysis by Location of Headquarters
4.3.4. Most Active Players: Analysis by Number of Technologies
5. SERVICE PROVIDERS LANDSCAPE
5.1. Chapter Overview
5.2. Long Acting Drug Delivery: Service Providers Landscape
5.2.1. Analysis by Year of Establishment
5.2.2. Analysis by Company Size
5.2.3. Analysis by Location of Headquarters
5.2.4. Analysis by Company Size and Location of Headquarters
5.2.5. Analysis by Location of Facilities
5.2.6. Analysis by Type of Service Provider(s)
5.2.7. Analysis by Scale of Operation
5.2.8. Analysis by Compatible Dosage Form(s)
5.2.9. Analysis by Scale of Operation and Compatible Dosage Form(s)
5.2.10. Analysis by Service(s) Offered
5.2.11. Analysis by Company Size and Service(s) Offered
5.2.12. Analysis by Year of Establishment, Location of Headquarters and Service(s) Offered
5.2.13. Analysis by Type of Molecule(s) Supported
5.2.14. Analysis by Type of Service Provider(s) and Type of Molecule(s) Supported
6. TECHNOLOGY COMPETITIVENESS ANALYSIS
6.1. Chapter Overview
6.2. Assumptions / Key Parameters
6.3. Methodology
6.4. Technology Competitiveness Analysis
6.4.1. Long Acting Drug Delivery Technologies offered by Small Companies
6.4.2. Long Acting Drug Delivery Technologies offered by Mid-sized Companies
6.4.3. Long Acting Drug Delivery Technologies offered by Large Companies
6.4.4. Long Acting Drug Delivery Technologies offered by Very Large Companies
7. COMPANY COMPETITIVENESS ANALYSIS
7.1. Chapter Overview
7.2. Assumptions / Key Parameters
7.3. Methodology
7.4. Company Competitiveness Analysis
7.4.1. Long Acting Drug Delivery Service Providers based in North America
7.4.2. Long Acting Drug Delivery Service Providers based in Europe
7.4.3. Long Acting Drug Delivery Service Providers based in Asia-Pacific
8. COMPANY PROFILES
8.1. Chapter Overview
8.2. Adare Pharma Solutions
8.2.1. Company Overview
8.2.2. Technology Portfolio
8.2.3. Service Portfolio
8.2.4. Recent Developments and Future Outlook
8.3. AMW
8.3.1. Company Overview
8.3.2. Technology Portfolio
8.3.3. Service Portfolio
8.3.4. Recent Developments and Future Outlook
8.4. Bostal Drug Delivery
8.4.1. Company Overview
8.4.2. Technology Portfolio
8.4.3. Service Portfolio
8.4.4. Recent Developments and Future Outlook
8.5. Creative Biolabs
8.5.1. Company Overview
8.5.2. Technology Portfolio
8.5.3. Service Portfolio
8.5.4. Recent Developments and Future Outlook
8.6. ForDoz Pharma
8.6.1. Company Overview
8.6.2. Technology Portfolio
8.6.3. Service Portfolio
8.6.4. Recent Developments and Future Outlook
8.7. InnoCore Pharmaceuticals
8.7.1. Company Overview
8.7.2. Technology Portfolio
8.7.3. Service Portfolio
8.7.4. Recent Developments and Future Outlook
8.8. Integral BioSystems
8.8.1. Company Overview
8.8.2. Technology Portfolio
8.8.3. Service Portfolio
8.8.4. Recent Developments and Future Outlook
8.9. LATITUDE Pharmaceuticals
8.9.1. Company Overview
8.9.2. Technology Portfolio
8.9.3. Service Portfolio
8.9.4. Recent Developments and Future Outlook
8.10. Navin Saxena Research and Technology Centre (NSRT)
8.10.1. Company Overview
8.10.2. Technology Portfolio
8.10.3. Service Portfolio
8.10.4. Recent Developments and Future Outlook
8.11. Samyang Biopharm
8.11.1. Company Overview
8.11.2. Technology Portfolio
8.11.3. Service Portfolio
8.11.4. Recent Developments and Future Outlook
9. PARTNERSHIPS AND COLLABORATIONS
9.1. Chapter Overview
9.2. Partnership Models
9.3. Long Acting Drug Delivery Technologies and Services: Partnerships and Collaborations
9.3.1. Analysis by Year of Partnership
9.3.2. Analysis by Type of Partnership
9.3.3. Analysis by Year and Type of Partnership
9.3.4. Analysis by Type of Partner
9.3.5. Analysis by Location of Headquarters of Partner
9.3.6. Analysis by Type of Partnership and Location of Headquarters of Partner
9.3.7. Most Active Players: Analysis by Number of Partnerships
9.3.8. Regional Analysis
9.3.8.1. Intercontinental and Intracontinental Deals
9.3.8.2. Local and International Deals
10. PUBLICATION ANALYSIS
10.1. Chapter Overview
10.2. Scope and Methodology
10.3. Long Acting Drug Delivery: Publication Analysis
10.3.1. Analysis by Year of Publication
10.3.2. Analysis by Type of Publication
10.3.3. Analysis by Most Popular Keywords
10.3.4. Most Popular Journals: Analysis by Number of Publications
10.3.5. Most Popular Publishers: Analysis by Number of Publications
10.3.6. Most Popular Copyright Holders: Analysis by Number of Publications
10.3.7. Key Funding Institutes: Analysis by Number of Publications
11. PATENT ANALYSIS
11.1. Chapter Overview
11.2. Scope and Methodology
11.3. Long Acting Drug Delivery: Patent Analysis
11.3.1. Analysis by Publication Year
11.3.2. Analysis by Type of Patent and Publication Year
11.3.3. Analysis by Geography
11.3.4. Analysis by CPC Symbols
11.3.5. Leading Industry Players: Analysis by Number of Patents
11.3.6. Analysis by Type of Organization
11.4. Patent Benchmark Analysis
11.4.1. Analysis by Patent Characteristics
11.5. Patent Valuation Analysis
12. GRANT ANALYSIS
12.1. Chapter Overview
12.2. Scope and Methodology
12.3. Long Acting Drug Delivery: Grant Analysis
12.3.1. Analysis by Year of Grant Award
12.3.2. Analysis by Amount Awarded
12.3.3. Analysis by Support Period
12.3.4. Analysis by Support Period and Funding Institute Center
12.3.5. Analysis by Type of Grant Application
12.3.6. Analysis by Purpose of Grant Award
12.3.7. Analysis By Activity Code
12.3.8. Analysis by NIH Spending Category
12.3.9. Analysis by Study Section Involved
12.3.10. Popular NIH Departments: Analysis by Number of Grants
12.3.11. Analysis by Type of Recipient Organization
12.3.12. Prominent Program Officers: Analysis by Number of Grants
12.3.13. Popular Recipient Organizations: Analysis by Number of Grants
12.3.14. Popular Recipient Organizations: Analysis by Grant Amount
12.3.15. Analysis by Region of Recipient Organizations
13. MARKET FORECAST AND OPPORTUNITY ANALYSIS
13.1. Chapter Overview
13.2. Key Assumptions and Forecast Methodology
13.3. Global Long Acting Drug Delivery Technologies Market, 2023-2035
13.3.1. Long Acting Drug Delivery Technologies Market: Analysis by Type of Payment Model Employed
13.3.1.1. Long Acting Drug Delivery Technologies Market for Upfront Payment, 2023-2035
13.3.1.2. Long Acting Drug Delivery Technologies Market for Milestone Payment, 2023-2035
13.3.2. Long Acting Drug Delivery Technologies Market: Analysis by Principle
13.3.2.1. Long Acting Drug Delivery Technologies Market for Manipulation of Drug Release from Delivery Systems, 2023-2035
13.3.2.2. Long Acting Drug Delivery Technologies Market for Manipulation of In Vivo Clearance, 2023-2035
13.3.3. Long Acting Drug Delivery Technologies Market: Analysis by Strategy
13.3.3.1. Long Acting Drug Delivery Technologies Market for Micro-encapsulation, 2023-2035
13.3.3.2. Long Acting Drug Delivery Technologies Market for Long Acting Implants, 2023-2035
13.3.3.3. Long Acting Drug Delivery Technologies Market for Multivesicular Liposomes, 2023-2035
13.3.3.4. Long Acting Drug Delivery Technologies Market for Nanocrystal Suspensions, 2023-2035
13.3.3.5. Long Acting Drug Delivery Technologies Market for Long Acting Hydrogels, 2023-2035
13.3.3.6. Long Acting Drug Delivery Technologies Market for Long Acting Microneedles, 2023-2035
13.3.3.7. Long Acting Drug Delivery Technologies Market for Chemical Modification, 2023-2035
13.3.3.8. Long Acting Drug Delivery Technologies Market for Protein Fusion, 2023-2035
13.3.4. Long Acting Drug Delivery Technologies Market: Analysis by Compatible Dosage Form
13.3.4.1. Long Acting Drug Delivery Technologies Market for Injectables, 2023-2035
13.3.4.2. Long Acting Drug Delivery Technologies Market for Implantables, 2023-2035
13.3.4.3. Long Acting Drug Delivery Technologies Market for Vaginal Dosage Forms, 2023-2035
13.3.4.4. Long Acting Drug Delivery Technologies Market for Topical / Transdermal Dosage Forms, 2023-2035
13.3.4.5. Long Acting Drug Delivery Technologies Market for Oral Dosage Forms, 2023-2035
13.3.4.6. Long Acting Drug Delivery Technologies Market for Other Dosage Forms, 2023-2035
13.3.5. Long Acting Drug Delivery Technologies Market: Analysis by Type of Molecule Delivered
13.3.5.1. Long Acting Drug Delivery Technologies Market for Small Molecules, 2023-2035
13.3.5.2. Long Acting Drug Delivery Technologies Market for Biologics, 2023-2035
13.3.5.3. Long Acting Drug Delivery Technologies Market for Other Molecules, 2023-2035
13.3.6. Long Acting Drug Delivery Technologies Market: Analysis by Type of Material Used
13.3.6.1. Long Acting Drug Delivery Technologies Market for Polymer-based, 2023-2035
13.3.6.2. Long Acting Drug Delivery Technologies Market for Non-polymer based, 2023-2035
13.3.7. Long Acting Drug Delivery Technologies Market: Analysis by Region
13.3.7.1. Long Acting Drug Delivery Technologies Market in North America, 2023-2035
13.3.7.2. Long Acting Drug Delivery Technologies Market in Europe, 2023-2035
13.3.7.3. Long Acting Drug Delivery Technologies Market in Asia-Pacific, 2023-2035
13.3.7.4. Long Acting Drug Delivery Technologies Market in Middle East and North Africa, 2023-2035
13.4. Global Long Acting Drug Delivery Services Market, 2023-2035
13.4.1. Long Acting Drug Delivery Services Market: Analysis by Compatible Dosage Form
13.4.1.1. Long Acting Drug Delivery Services Market for Injectables, 2023-2035
13.4.1.2. Long Acting Drug Delivery Services Market for Implantables, 2023-2035
13.4.1.3. Long Acting Drug Delivery Services Market for Vaginal Dosage Forms, 2023-2035
13.4.1.4. Long Acting Drug Delivery Services Market for Topical / Transdermal Dosage Forms, 2023-2035
13.4.1.5. Long Acting Drug Delivery Services Market for Oral Dosage Forms, 2023-2035
13.4.1.6. Long Acting Drug Delivery Services Market for Other Dosage Forms, 2023-2035
13.4.2. Long Acting Drug Delivery Services Market: Analysis by Type of Molecule Supported
13.4.2.1. Long Acting Drug Delivery Services Market for Small Molecules, 2023-2035
13.4.2.2. Long Acting Drug Delivery Services Market for Biologics, 2023-2035
13.4.2.3. Long Acting Drug Delivery Services Market for Other Molecules, 2023-2035
13.4.3. Long Acting Drug Delivery Services Market: Analysis by Region
13.4.3.1. Long Acting Drug Delivery Services Market in North America, 2023-2035
13.4.3.2. Long Acting Drug Delivery Services Market in Europe, 2023-2035
13.4.3.3. Long Acting Drug Delivery Services Market in Asia-Pacific, 2023-2035
14. CONCLUSION
15. INTERVIEW TRANSCRIPTS
16. APPENDIX 1: TABULATED DATA
17. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

ページTOPに戻る

Table of Contents

Summary

The long acting drug market is likely to grow at a CAGR of 13% during the forecast period 2023-2035.

In recent years, there has been a pronounced shift in the pharmaceutical landscape away from conventional drug delivery methods towards the adoption of long-acting drug delivery systems. These systems offer sustained drug action over extended periods following a single administration, ensuring the maintenance of optimal therapeutic levels within a patient's system for weeks, months, or even years. This transformative transition has significantly impacted various medical domains, including ophthalmology, oncology, neurology, and infectious diseases, presenting promising avenues for treatment.

The adoption of long-acting drug delivery systems brings forth numerous advantages. These include improved patient adherence and compliance, reduced dosing frequency, minimized risks associated with erratic drug usage, and heightened convenience for patients. Additionally, the rise of long-acting vaginal rings as multipurpose prevention technologies for women highlights the expanding scope and demand for such innovations in the medical realm. Integral to the success of these long-acting drug formulations is the meticulous selection of an appropriate dosage form, such as long-acting implants, injectables, vaginal, oral, or topical/transdermal preparations, coupled with strategic implementation of methodologies like micro-encapsulation, nanocrystal suspensions, long-acting hydrogels, and microneedles. This thoughtful amalgamation ensures enhanced drug biodistribution and facilitates targeted therapeutic effects, thereby enabling extended release or duration of action.

Propelled by a relentless pace of innovation in developing these state-of-the-art technologies and driven by a burgeoning market demand for long-acting drug solutions, the long-acting drugs technology and services market is poised for substantial expansion during the forecast period.

Report Coverage
 An executive summary of the key insights captured in research. It offers a high-level view on the current state of long-acting drug delivery technologies and services market and its likely evolution in the mid-long term.
 Overview of long-acting drug delivery and types of long-acting drug delivery systems. Additionally, it highlights the underlying principles and strategies associated with long-acting drug delivery.
 Detailed assessment of the current technology landscape of long-acting drug delivery technologies, based on several relevant parameters, such as principle, strategy, type of material used, compatible dosage form(s), extended dosing interval(s), type of molecule(s) delivered, highest phase of development, number of approved drugs and therapeutic area(s).
 Detailed assessment of the overall service providers landscape of the companies offering contract services related to long-acting drug delivery, based on several relevant parameters, such as year of establishment, company size, location of headquarters, location of facilities, type of service provider(s), scale of operation, compatible dosage form(s), service(s) offered and type of molecule(s) supported.
 A detailed technology competitiveness analysis of long-acting drug delivery technologies based on developer power and technology strength.
 A detailed company competitiveness analysis of long-acting drug delivery service providers based on company strength and service strength
 Detailed profiles of prominent (shortlisted based on a proprietary criterion) players developing technologies and offering services in the domain of long-acting drug delivery, across North America, Europe and Asia-Pacific. Each profile features a brief overview of the company, details related to its technology portfolio, service portfolio, recent developments and an informed future outlook.
 A detailed analysis of the recent partnerships inked between stakeholders engaged in this domain, since 2018, covering acquisitions, manufacturing agreements, product development and commercialization agreements, service alliance, technology licensing agreements, and other relevant agreements.
 A detailed analysis of over 570 peer-reviewed, scientific articles on research related to long-acting drug delivery, based on several relevant parameters, such as year of publication, type of publication and popular keywords. It also provides information on top journals, top publishers, top copyright holders and key funding institutes (in terms of number of articles published).
 An insightful analysis of various patents that have been filed / granted related to long-acting drug delivery, since 2018, taking into consideration parameters, such as publication year, geographical region, CPC symbols, type of organization and leading players.
 A detailed review of academic grants that have been awarded to various research institutes for projects focused on long-acting drug delivery, since 2018, based on several parameters, such as year of grant award, amount awarded, support period, type of funding institute center, grant application, purpose of grant award, grant activity code, NIH spending category, study section involved, popular NIH departments and type of recipient organization.
 A comprehensive market forecast and opportunity analysis, highlighting the future potential of the market till the year 2035. We have segregated the current and upcoming opportunity based on principle, strategy, compatible dosage form, type of molecule delivered, type of material used and key geographical regions

Key Market Companies
 Adare Pharma Solutions
 AMW
 Bostal Drug Delivery
 Creative Biolabs
 ForDoz Pharma
 Innocore Pharmaceuticals
 Integral BioSystems
 LATITUDE Pharmaceuticals
 Navin Saxena Research and Technology Centre (NSRT)
 Samyang Biopharm

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野の最新刊レポート

本レポートと同分野の最新刊レポートはありません。

Roots Analysis 社の最新刊レポート

本レポートと同じKEY WORD（）の最新刊レポート

本レポートと同じKEY WORDの最新刊レポートはありません。

よくあるご質問

Roots Analysis社はどのような調査会社ですか?

Roots Analysisは2013年設立の医薬品・医療機器が専門の調査会社です。医薬品の製造委託や創薬のデジタル化など、最新の医薬業界の分析を行っています。もっと見る

調査レポートの納品までの日数はどの程度ですか?

在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。

注文の手続きはどのようになっていますか?

1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。

お支払方法の方法はどのようになっていますか?

納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
お客様よりデータリソース社へ（通常は円払い）の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。

データリソース社はどのような会社ですか?

当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。

サマリー

目次

Summary

Table of Contents

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

本レポートと同分野の最新刊レポート

Roots Analysis 社の最新刊レポート

本レポートと同じKEY WORD（）の最新刊レポート

よくあるご質問

Roots Analysis社はどのような調査会社ですか?

調査レポートの納品までの日数はどの程度ですか?

注文の手続きはどのようになっていますか?

お支払方法の方法はどのようになっていますか?

データリソース社はどのような会社ですか?